Moderna beats Q4 revenue estimate

Madna Earnings Report Analysis - Q4 2024 & Outlook

Key Concepts:

• Madna: A biotechnology company facing declining sales post-pandemic.
• FDA Review Delay (Flu Vaccine): The US Food and Drug Administration’s decision not to review Madna’s flu vaccine application.
• INT Studies: Investigational New Drug studies, specifically relating to Madna’s cancer treatment programs.
• Melanoma Data (2026): Anticipated Phase 3 clinical trial data readout for Madna’s melanoma cancer treatment.
• Break-Even Target (2028): Madna’s stated goal to achieve profitability by 2028.
• Ex-US vs. US Dynamics: The differing regulatory landscapes and market conditions in regions outside the United States compared to the US.
• CO Sales: Sales related to COVID-19 vaccines.
• Peak Sales: The maximum projected revenue a product is expected to generate.

I. Q4 2024 Earnings Overview

Madna’s Q4 revenue and earnings met Wall Street estimates, however, the company continues to experience significant year-over-year sales declines as demand for its COVID-19 vaccines diminishes. The earnings report indicated revenues were largely in line with pre-announced figures from January. Importantly, expenses were lower than anticipated, providing some positive momentum. The company reiterated its focus on expense control as a key driver for stock performance, aiming to achieve break-even by 2028 with revenues expected to remain relatively flat in 2026. Andrew Sai, Managing Director at Jeffre, highlighted that the lower-than-expected expenses were a source of relief for investors.

II. FDA Flu Vaccine Application Delay – A Cause for Concern?

The FDA’s decision not to review Madna’s flu vaccine application was described as “strange and unusual.” Sai speculated that political factors might be contributing to the delay, noting that previous FDA meetings over the past two years had not indicated concerns regarding the Phase 3 study design. While acknowledging concern regarding the timing of potential US approval and its impact on medium-term sales, Sai emphasized that this is primarily a US-specific issue. Regulatory reviews are progressing positively in the EU, Australia, and Canada. This contrast between US and ex-US regulatory pathways is a key dynamic to watch.

III. The Importance of Cancer Treatments (INT Studies)

Bloomberg Intelligence analysts suggest Madna’s success hinges on its cancer treatment pipeline, particularly given the challenges with the flu vaccine. Sai generally agreed, stating that the upcoming Phase 3 melanoma data readout in 2026 is crucial. He estimated potential peak sales for the melanoma treatment could exceed $1 billion, significantly contributing to Madna’s top line, which is projected at approximately $3 billion for the current year. However, Sai stressed the importance of evaluating the INT personalized vaccine’s efficacy in other solid tumors, specifically renal cell carcinoma and lung cancer, as these indications could represent even larger market opportunities with data expected in 2026-2027. He emphasized that positive data from these trials is necessary to bolster confidence in Madna’s future revenue growth.

IV. Management Outlook & Revenue Projections

Madna’s management maintains a revenue growth forecast of up to 10% for the current year, while consensus estimates predict flat revenue. Sai views even flat revenue as positive, given the decline in COVID-19 vaccine sales. He expressed optimism regarding potential growth in ex-US COVID-19 vaccine sales and the possibility of manufacturing revenue from facilities in the EU and other regions. The company anticipates a year-over-year decline in US sales, but a potential resurgence in US vaccination rates would be a positive catalyst.

V. Cautious Optimism & Sales Forecast

Sai expressed cautious optimism, suggesting that sales are likely to be flat rather than decline. He indicated that a decline of $100-200 million would be acceptable, but a “meaningful drop” would be concerning. He believes that maintaining relatively stable sales overall is achievable.

VI. Notable Quotes

• Andrew Sai: “I think it's a strange unusual circumstance [regarding the FDA delay]. It makes people including me wonder whether this is… related in part due to politics.”
• Andrew Sai: “I think sales will be flattish would be my best guess. Even if it's down 100 200 million I think that's fine to be clear. Just to me it's flattish enough. I just don't want a meaningful drop which I don't think happens.”

VII. Technical Terms & Concepts

• Phase 3 Clinical Trial: The final stage of clinical trials, involving a large number of patients, to confirm efficacy and monitor side effects.
• INT Studies: Investigational New Drug studies, a process for gaining FDA approval to test new drugs in humans.
• Regulatory Review: The process by which regulatory agencies (like the FDA) evaluate the safety and efficacy of a drug or vaccine.
• Break-Even Point: The point at which total revenue equals total costs, resulting in zero profit or loss.

Conclusion:

Madna’s recent earnings report presents a mixed picture. While the company met expectations and demonstrated expense control, the FDA’s delay in reviewing the flu vaccine application and the ongoing decline in COVID-19 vaccine demand pose significant challenges. The success of Madna’s cancer treatment pipeline, particularly the melanoma program and potential expansion into other solid tumors, is critical for future growth. Management’s focus on expense management and the potential for ex-US revenue growth offer some optimism, but the company’s future trajectory remains contingent on positive clinical trial data and a favorable regulatory environment. The overall sentiment is cautiously optimistic, with a focus on achieving flat sales and progressing towards the 2028 break-even target.